Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,240,521
  • Shares Outstanding, K 101,849
  • Annual Sales, $ 36,280 K
  • Annual Income, $ -481,190 K
  • EBIT $ -538 M
  • EBITDA $ -529 M
  • 60-Month Beta 1.76
  • Price/Sales 33.92
  • Price/Cash Flow N/A
  • Price/Book 1.27

Options Overview Details

View History
  • Implied Volatility 93.53% ( +2.65%)
  • Historical Volatility 69.59%
  • IV Percentile 98%
  • IV Rank 75.19%
  • IV High 106.41% on 11/15/24
  • IV Low 54.50% on 08/21/24
  • Put/Call Vol Ratio 0.67
  • Today's Volume 1,979
  • Volume Avg (30-Day) 2,394
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 61,357
  • Open Int (30-Day) 51,406

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.35
  • Number of Estimates 12
  • High Estimate -0.88
  • Low Estimate -1.61
  • Prior Year -1.46
  • Growth Rate Est. (year over year) +7.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.79 +3.31%
on 12/19/24
16.01 -23.92%
on 12/02/24
-0.94 (-7.16%)
since 11/20/24
3-Month
11.79 +3.31%
on 12/19/24
21.94 -44.48%
on 09/23/24
-9.70 (-44.33%)
since 09/20/24
52-Week
11.79 +3.31%
on 12/19/24
34.87 -65.07%
on 02/29/24
-17.44 (-58.88%)
since 12/20/23

Most Recent Stories

More News
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 12.18 (+0.83%)
Intellia Therapeutics Announces FDA Grants RMAT Designation for CRISPR-Based Therapy nexiguran ziclumeran in Treating Hereditary ATTR Amyloidosis

Intellia Therapeutics receives FDA RMAT designation for nexiguran ziclumeran, a CRISPR therapy for hereditary ATTR amyloidosis.Quiver AI SummaryIntellia Therapeutics, Inc. announced that the U.S. FDA has...

NTLA : 12.18 (+0.83%)
2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025

Both penny stocks are a 'strong buy' on Wall Street.

CABA : 2.38 (+3.03%)
$SPX : 5,930.85 (+1.09%)
NTLA : 12.18 (+0.83%)
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

NTLA : 12.18 (+0.83%)
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Shares of biotech Intellia Therapeutics (NASDAQ: NTLA) are down by around 33% over the past 30 days, amid the publication of some new data from an early stage clinical trial on Nov. 16 and its third-quarter...

NTLA : 12.18 (+0.83%)
Intellia Therapeutics Reports Promising Phase 1 Trial Results for Nexiguran Ziclumeran in ATTR Amyloidosis

Intellia Therapeutics announces positive Phase 1 trial results for nex-z in ATTR amyloidosis, indicating significant TTR reduction and disease stabilization.Quiver AI SummaryIntellia Therapeutics announced...

NTLA : 12.18 (+0.83%)
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

NTLA : 12.18 (+0.83%)
3 Fast-Growing Stocks Analysts See Doubling in Price

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

IMCR : 28.33 (-0.33%)
GHRS : 6.85 (-7.31%)
NTLA : 12.18 (+0.83%)
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

NTLA : 12.18 (+0.83%)
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

There's nothing bearish at all about what it reported recently.

NTLA : 12.18 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 13.07
2nd Resistance Point 12.76
1st Resistance Point 12.47
Last Price 12.18
1st Support Level 11.87
2nd Support Level 11.56
3rd Support Level 11.27

See More

52-Week High 34.87
Fibonacci 61.8% 26.05
Fibonacci 50% 23.33
Fibonacci 38.2% 20.61
Last Price 12.18
52-Week Low 11.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar